Loading filters...
50 results(scroll for more)
Immunotherapyadvanced2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.
Yap TA et al. Nat Med. 2026
Uvealadvanced2026
Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma.
Yang K et al. Melanoma Res. 2026
cytokineAll Stages2026
Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?
Woodford R et al. Br J Cancer. 2026
Immunotherapyadvanced2026
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.
Lorigan P et al. Eur J Cancer. 2026
cytokineadvanced2026
Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma.
Said JT et al. JAMA Dermatol. 2026
ImmunotherapyEarly (I-II)2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
Hoeijmakers LL et al. Nat Med. 2026
Uvealadvanced2026
Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma.
Piperno-Neumann S et al. Ann Oncol. 2026
Immunotherapyadvanced2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
Albrecht LJ et al. Eur J Cancer. 2026
ImmunotherapyEarly (I-II)2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.
Kendra KL et al. Nat Cancer. 2026
cytokineadvanced2026
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.
Lassen U et al. ESMO Open. 2026
AdjuvantEarly (I-II)2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.
Tetzlaff M et al. ESMO Open. 2026
Immunotherapyadvanced2026
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
Hassel JC et al. Ann Oncol. 2026
AdjuvantEarly (I-II)2026
4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study.
Janssen JC et al. Eur J Cancer. 2026
ImmunotherapyEarly (I-II)2026
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.
Rawson RV et al. Ann Oncol. 2026
BRAF V600Early (I-II)2026
Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3.
Devoldere A et al. Melanoma Res. 2026
ImmunotherapyAll Stages2026
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).
Nardin C et al. Br J Dermatol. 2026
AdjuvantAll Stages2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Dummer R et al. Lancet Oncol. 2026
Immunotherapyadvanced2026
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial.
Haferkamp S et al. Br J Dermatol. 2026
cytokineadvanced2026
IFNγ-dependent metabolic reprogramming restrains an immature, pro-metastatic lymphatic state in melanoma.
Karakousi T et al. Cancer Cell. 2026
cytokineadvanced2026
Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance.
Haist M et al. Cancer Cell. 2026
BRAF V600Early (I-II)2026
Updates in adjuvant and neoadjuvant therapies for resectable cutaneous melanoma.
Hadfield MJ et al. J Am Acad Dermatol. 2026
cytokineAll Stages2026
Intralesional Interleukin-2 Therapy for Treatment of Cutaneous Squamous Cell Carcinoma.
Giacomantonio CA et al. JAMA Dermatol. 2026
BRAF V600All Stages2026
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanoma.
Namir G et al. Melanoma Res. 2026
ImmunotherapyEarly (I-II)2026
Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands.
Wilson MJ et al. Eur J Cancer. 2026
Uvealadvanced2026
Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.
Ramelyte E et al. Clin Cancer Res. 2026
Uvealadvanced2026
Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.
Kissinger CR et al. Melanoma Res. 2026
AdjuvantEarly (I-II)2026
Contralateral axillary sentinel lymph node in chest wall melanoma: first documented case and narrative review of the literature.
Davies L et al. Melanoma Res. 2026
Uvealadvanced2026
Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report.
Smarsly D et al. ESMO Open. 2026
ImmunotherapyAll Stages2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.
Campbell KM et al. Cancer Discov. 2026
BRAF V600advanced2026
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.
Dummer R et al. Clin Cancer Res. 2026
Immunotherapyadvanced2026
Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
van den Hoek L et al. Lancet Oncol. 2026
Immunotherapyadvanced2026
Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.
Granhøj JS et al. Clin Cancer Res. 2026
ImmunotherapyEarly (I-II)2026
Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.
Wang G et al. Cancer Cell. 2026
Immunotherapyadvanced2026
Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.
Carlino MS et al. JAMA Oncol. 2026
ImmunotherapyAll Stages2026
Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.
Ivanova M et al. Melanoma Res. 2026
BRAF V600All Stages2026
Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to 2021.
Mullins KR et al. Melanoma Res. 2026
Immunotherapyadvanced2026
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Azenkot T et al. Melanoma Res. 2026
Immunotherapyadvanced2026
Immune checkpoint inhibitor-associated uveitis in metastatic melanoma: case report and literature review.
Akcay P et al. Melanoma Res. 2026
BRAF V600advanced2026
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Piha-Paul SA et al. ESMO Open. 2026
ImmunotherapyAll Stages2025
Literature case analysis of immune checkpoint inhibitors-associated lipodystrophy.
Zhao Z et al. Melanoma Res. 2025
Immunotherapyadvanced2025
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response.
Trim E et al. Pigment Cell Melanoma Res. 2025
Uvealadvanced2025
Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations.
Del Carpio LP et al. Eur J Cancer. 2025
Uvealadvanced2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Sato T et al. Clin Cancer Res. 2025
Uvealadvanced2025
How we treat patients with metastatic uveal melanoma.
Saldanha EF et al. ESMO Open. 2025
Immunotherapyadvanced2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Wong MK et al. J Clin Oncol. 2025
Immunotherapyadvanced2025
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
Robert C et al. Eur J Cancer. 2025
Immunotherapyadvanced2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047.
Lipson EJ et al. Clin Cancer Res. 2025
ImmunotherapyAll Stages2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.
Lipson EJ et al. Eur J Cancer. 2025
Immunotherapyadvanced2025
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
Pandit-Taskar N et al. Melanoma Res. 2025
Immunotherapyadvanced2025
Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
Pedersen S et al. Eur J Cancer. 2025